EUCTR2007-005393-31-BG进行中（未招募）不适用
A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Evaluate Efficacy and Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy. - FINDE: Fentanyl In Neoplastic Disease Efficacy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 years or older.
- •2. A medically documented diagnosis of cancer.
- •3. Use of a fixed around-the-clock dose of an opioid or a fixed combination of opioids as maintenance therapy for pain relief with a dose equivalent of at least 60 mg of oral morphine/day, or at least 25 µg of transdermal fentanyl/hour, or at least 30 mg of oral oxycodone daily or at least 8 mg of oral hydromorphone daily. Patients must be taking current opioid treatment for at least 7 days prior to the first dose of study medication.
- •4. Current use of medication for BTP.
- •5. At least one BTP episode per day with peak intensity of at least 4 on the numerical pain scale (NPS) at pain onset; no more than 4 BTP episodes per day.
- •6. The flow rate of inhalation of at least 20 L/min assessed by inspiratory flow meter (the highest of two readings will be used).
- •7. Karnofsky Performance Status 40 or better.
- •8. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Uncontrolled or rapidly increasing BTP.
- •2. Symptomatic intracranial tumors or cerebral metastases.
- •3. Persistent, symptomatic asthma despite medication, as defined by daily symptoms, frequent exacerbations, frequent nocturnal asthma symptoms, predicted FEV1 = 60% or personal best PEFR = 60%.
- •4. Patients unable to use the inhaler (e.g. based on the use of training inhaler).
- •5. Inadequate lung function, as defined by PEFR < 60 %.
- •6. Hypersensitivities, allergies or contraindications to fentanyl or any compounds in the study medication.
- •7. A recent history of alcohol or substance abuse (in the past 1 year).
- •8. Chemotherapy with a drug not used before in this patient within 30 days of the beginning of the titration phase.
- •9. Radiotherapy to the thorax or the BTP target areas within 30 days of the beginning of the titration phase.
- •10. Cognitive impairment or any neurological or psychiatric disease which could compromise the ability of the patient to complete the assessments.
- •11. Participation in a prior clinical study with Fentanyl TAIFUN®.
- •12. Participation in any clinical study with experimental drug within 30 days of the study medication.
- •13. Any clinical condition (e.g. severe hepatic impairment) or medical history which, in the opinion of the investigator would not allow for the safe completion of the study or the safe administration of the study drug (e.g. elderly or cachectic patient on the lowest dose of maintenance opioid therapy).
- •14. Pre-menopausal women (last menstruation < 1 year prior to the screening visit) who:
- •- are not surgically sterile and/or
- •- have a positive pregnancy test at baseline visit and/or
- •- are of childbearing potential and are not practicing an acceptable means of birth control or do not plan to continue using this method throughout the study and/or are nursing.
研究者
相似试验
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with advanced breast cancer who have not yet been treated with drugs for breast cancer that has returned or is growing again and can not be removed by surgery, or that has spread to different parts of the body. Study has two groups: All patients will be treated with docetaxel. In addition, one group will receive IMC-1121B, the other group an inactive substance. Neither the patient nor the doctor will know the treatment group.HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast CancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2008-001727-65-SKImClone LLC1,144
进行中（未招募）
不适用
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast CancerHER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-001727-65-GRImClone LLC1,113
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with advanced breast cancer who have not yet been treated with drugs for breast cancer that has returned or is growing again and can not be removed by surgery, or that has spread to different parts of the body. Study has two groups: All patients will be treated with docetaxel. In addition, one group will receive IMC-1121B, the other group an inactive substance. Neither the patient nor the doctor will know the treatment group.HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast CancerMedDRA version: 17.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2008-001727-65-BEImClone LLC1,113
进行中（未招募）
不适用
A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Evaluate Efficacy and Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy. - FINDE: Fentanyl In Neoplastic Disease EfficacyBreakthrough pain in opioid tolerant cancer patients.EUCTR2007-005393-31-FIAkela Pharma Inc180
进行中（未招募）
1 期
Study investigating new drug, IMC-1121B, in patients with advanced breast cancer who have not yet been treated with drugs for breast cancer that has returned or is growing again and can not be removed by surgery, or that has spread to different parts of the body. Study has two groups: All patients will be treated with docetaxel. In addition, one group will receive IMC-1121B, the other group an inactive substance. Neither the patient nor the doctor will know the treatment group.HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast CancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2008-001727-65-CZImClone LLC1,144